Better Detection and Treatment for Mold Exposure: Improving Outcomes for Patients

by Matt Pratt-Hyatt, PhD

References:

1. Bennett JW, Klich M. Mycotoxins. Clin Microbiol Rev. 2003;16(3):497-516.

2. Auger PL, Gourdeau P, Miller JD. Clinical experience with patients suffering from a chronic fatigue-like syndrome and repeated upper respiratory infections in relation to airborne molds. Am J Ind Med. 1994;25(1):41-42.

3. Hodgson MJ, Morey P, Leung WY, et al. Building-associated pulmonary disease from exposure to Stachybotrys chartarum and Aspergillus versicolor. J Occup Environ Med. 1998;40(3):241-249.

4. Howard DH. Pathogenic fungi in humans and animals. 2nd ed. New York: Marcel Dekker; 2003.

5. Hassan YI, Watts C, Li XZ, Zhou T. A novel Peptide-binding motifs inference approach to understand deoxynivalenol molecular toxicity. Toxins (Basel). 2015;7(6):1989-2005.

6. Pace JG, Watts MR, Canterbury WJ. T-2 mycotoxin inhibits mitochondrial protein synthesis. Toxicon. 1988;26(1):77-85.

7. Chung YJ, Zhou HR, Pestka JJ. Transcriptional and posttranscriptional roles for p38 mitogen-activated protein kinase in upregulation of TNF-alpha expression by deoxynivalenol (vomitoxin). Toxicol Appl Pharmacol. 2003;193(2):188-201.

8. Zhou HR, Islam Z, Pestka JJ. Rapid, sequential activation of mitogen-activated protein kinases and transcription factors precedes proinflammatory cytokine mRNA expression in spleens of mice exposed to the trichothecene vomitoxin. Toxicol Sci. 2003;72(1):130-142.

9. Fontaine T, Delangle A, Simenel C, et al. Galactosaminogalactan, a new immunosuppressive polysaccharide of Aspergillus fumigatus. PLoS Pathog. 2011;7(11):e1002372.

10. Pahl HL, Krauss B, Schulze-Osthoff K, et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J Exp Med. 1996;183(4):1829-1840.

11. Corrier DE. Mycotoxicosis: mechanisms of immunosuppression. Vet Immunol Immunopathol. 1991;30(1):73-87.

12. Huynh VL, Gerdes RG, Lloyd AB. Synthesis and degradation of aflatoxins by Aspergillus parasiticus. II. Comparative toxicity and mutagenicity of aflatoxin B1 and its autolytic breakdown products. Aust J Biol Sci. 1984;37(3):123-129.

13. Cavalieri EL, Li KM, Balu N, et al. Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis. 2002;23(6):1071-1077.

14. Fehr M, Pahlke G, Fritz J, et al. Alternariol acts as a topoisomerase poison, preferentially affecting the IIalpha isoform. Mol Nutr Food Res. 2009;53(4):441-451.

15. More TT, Yan S, Tyagi RD, Surampalli RY. Potential use of filamentous fungi for wastewater sludge treatment. Bioresour Technol. 2010;101(20):7691-7700.

16. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect. 2010;118(6):818-824.

17. Tao Y, Xie S, Xu F, et al. Ochratoxin A: Toxicity, oxidative stress and metabolism. Food Chem Toxicol. 2018;112:320-331.

18. Nielsen KF, Gravesen S, Nielsen PA, Andersen B, Thrane U, Frisvad JC. Production of mycotoxins on artificially and naturally infested building materials. Mycopathologia. 1999;145(1):43-56.

19. Vonberg RP, Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect. 2006;63(3):246-254.

20. Doczi I, Gyetvai T, Kredics L, Nagy E. Involvement of Fusarium spp. in fungal keratitis. Clin Microbiol Infect. 2004;10(9):773-776.

21. Jarvis BB, Lee YW, Comezoglu SN, Yatawara CS. Trichothecenes produced by Stachybotrys atra from Eastern Europe. Appl Environ Microbiol. 1986;51(5):915-918.

22. Escobar J, Loran S, Gimenez I, et al. Occurrence and exposure assessment of Fusarium mycotoxins in maize germ, refined corn oil and margarine. Food Chem Toxicol. 2013;62:514-520.

23. Sharpe R, Thornton CR, Osborne NJ. Modifiable factors governing indoor fungal diversity and risk of asthma. Clin Exp Allergy. 2014;44(5):631-641.

24. Grant G, Hunter CA, Flannigan B, Bravery AF. The moisture requirements of moulds isolated from domestic buildings. Int Biodeterior. 1989;25:259-284.

25. Mitchell NJ, Bowers E, Hurburgh C, Wu F. Potential economic losses to the US corn industry from aflatoxin contamination. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2016;33(3):540-550.

26. Solfrizzo M, Gambacorta L, Visconti A. Assessment of multi-mycotoxin exposure in southern Italy by urinary multi-biomarker determination. Toxins (Basel). 2014;6(2):523-538.

27. Stahnke H, Kittlaus S, Kempe G, Alder L. Reduction of matrix effects in liquid chromatography-electrospray ionization-mass spectrometry by dilution of the sample extracts: how much dilution is needed? Anal Chem. 2012;84(3):1474-1482.

28. JSC T, GL L. Drug-Testing technologies and applications. In: RC W, HY T, eds. Drug-testing technologies and applications. Totowa: Humana Press; 2005:29-69.

29. Escriva L, Font G, Manyes L, Berrada H. Studies on the Presence of Mycotoxins in Biological Samples: An Overview. Toxins (Basel). 2017;9(8).

30. Kimura Y, Tani S, Hayashi A, et al. Nematicidal activity of 5-hydroxymethyl-2-furoic acid against plant-parasitic nematodes. Z Naturforsch C. 2007;62(3-4):234-238.

31. Karich A, Kleeberg SB, Ullrich R, Hofrichter M. Enzymatic Preparation of 2,5-Furandicarboxylic Acid (FDCA)-A Substitute of Terephthalic Acid-By the Joined Action of Three Fungal Enzymes. Microorganisms. 2018;6(1).

32. Horner WE, Helbling A, Salvaggio JE, Lehrer SB. Fungal allergens. Clin Microbiol Rev. 1995;8(2):161-179.

33. Sun CA, Wang LY, Chen CJ, et al. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. Carcinogenesis. 2001;22(8):1289-1294.

34. Emmett M. Acetaminophen toxicity and 5-oxoproline (pyroglutamic acid): a tale of two cycles, one an ATP-depleting futile cycle and the other a useful cycle. Clin J Am Soc Nephrol. 2014;9(1):191- 200.

35. Darmaun D, Smith SD, Sweeten S, Hartman BK, Welch S, Mauras N. Poorly controlled type 1 diabetes is associated with altered glutathione homeostasis in adolescents: apparent resistance to Nacetylcysteine supplementation. Pediatr Diabetes. 2008;9(6):577-582.

36. Lea T, Steien K, Stormer FC. Mechanism of ochratoxin A-induced immunosuppression. Mycopathologia. 1989;107(2-3):153-159.

37. Boorman GA, Hong HL, Dieter MP, et al. Myelotoxicity and macrophage alteration in mice exposed to ochratoxin A. Toxicol Appl Pharmacol. 1984;72(2):304-312.

38. Park SH, Kim D, Kim J, Moon Y. Effects of Mycotoxins on mucosal microbial infection and related pathogenesis. Toxins (Basel). 2015;7(11):4484-4502.

39. Peitzch, Bloom, Haase, Must, Larson. Remediation of mould damaged building materials-efficiency of a broad spectrum of treatments. Journal of Environmental Monitoring. Vol 142012:908-915.

40. Hope J. A review of the mechanism of injury and treatment approaches for illness resulting from exposure to water-damaged buildings, mold, and mycotoxins. ScientificWorldJournal. 2013;2013:767482.

41. Wild CP, Gong YY. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis. 2010;31(1):71-82.

42. Praneenararat S. Fungal infection of the colon. Clin Exp Gastroenterol. 2014;7:415-426.

43. Ponikau JU, Sherris DA, Kern EB, et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc. 1999;74(9):877-884.

44. Shaw W, Kassen E, Chaves E. Assesssment of antifungal drug therapy in autism by measurement of suspected microbial metabolites in urine with gas chromatography-mass spectrometry. Clinical Practice of Alternative Medicine. 2000;1:15-20.

45. Ponikau JU, Sherris DA, Weaver A, Kita H. Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial. J Allergy Clin Immunol. 2005;115(1):125-131.

46. Liang KL, Su MC, Shiao JY, et al. Amphotericin B irrigation for the treatment of chronic rhinosinusitis without nasal polyps: a randomized, placebo-controlled, double-blind study. Am J Rhinol. 2008;22(1):52-58.

47. Ponikau JU, Sherris DA, Kita H, Kern EB. Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2002;110(6):862-866.

48. Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother. 1998;42(6):1412-1416.

49. Offner F, Krcmery V, Boogaerts M, et al. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob Agents Chemother. 2004;48(12):4808- 4812. ++